Par Drugs [PAR] vs Bal Pharma [BALPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Par Drugs and Chemicals Ltd. wins in 11 metrics, Bal Pharma Ltd. wins in 6 metrics, with 1 ties. Par Drugs and Chemicals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Par Drugs and Chemicals Ltd. | Bal Pharma Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.15 | 15.34 | Par Drugs and Chemicals Ltd. |
| Price-to-Book Ratio | 1.37 | 1.57 | Par Drugs and Chemicals Ltd. |
| Debt-to-Equity Ratio | 0.00 | 197.73 | Tie |
| PEG Ratio | N/A | 0.06 | N/A |
| EV/EBITDA | 5.55 | 11.21 | Par Drugs and Chemicals Ltd. |
| Profit Margin (TTM) | 13.23% | 2.63% | Par Drugs and Chemicals Ltd. |
| Operating Margin (TTM) | 6.75% | 7.20% | Bal Pharma Ltd. |
| EBITDA Margin (TTM) | 6.75% | 7.20% | Bal Pharma Ltd. |
| Return on Equity | 14.47% | 9.32% | Par Drugs and Chemicals Ltd. |
| Return on Assets (TTM) | 8.97% | 2.15% | Par Drugs and Chemicals Ltd. |
| Free Cash Flow (TTM) | $149.34M | $15.28M | Par Drugs and Chemicals Ltd. |
| Dividend Yield | N/A | 1.63% | N/A |
| 1-Year Return | -11.42% | -16.65% | Par Drugs and Chemicals Ltd. |
| Price-to-Sales Ratio (TTM) | 1.34 | 0.40 | Bal Pharma Ltd. |
| Enterprise Value | $1.08B | $2.70B | Bal Pharma Ltd. |
| EV/Revenue Ratio | 1.07 | 0.87 | Bal Pharma Ltd. |
| Gross Profit Margin (TTM) | 56.21% | 47.36% | Par Drugs and Chemicals Ltd. |
| Revenue per Share (TTM) | $82 | $184 | Bal Pharma Ltd. |
| Earnings per Share (Diluted) | $10.86 | $5.09 | Par Drugs and Chemicals Ltd. |
| Beta (Stock Volatility) | -0.39 | 0.35 | Par Drugs and Chemicals Ltd. |
Par Drugs and Chemicals Ltd. vs Bal Pharma Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd. | 7.75% | 9.88% | 7.00% | 7.59% | -7.96% | -8.14% |
| Bal Pharma Ltd. | 1.84% | 3.22% | 10.10% | 31.09% | 17.86% | 20.21% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd. | -11.42% | -57.49% | 26.63% | 250.22% | 250.22% | 250.22% |
| Bal Pharma Ltd. | -16.65% | -2.22% | -11.24% | -2.11% | 212.28% | 161.58% |
Performance & Financial Health Analysis: Par Drugs and Chemicals Ltd. vs Bal Pharma Ltd.
| Metric | PAR | BALPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.36B | ₹1.24B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 14,047 | 7,922 |
| 90 Day Avg. Volume | 8,813 | 12,055 |
| Last Close | ₹93.40 | ₹87.78 |
| 52 Week Range | ₹78.05 - ₹122.43 | ₹60.00 - ₹106.50 |
| % from 52W High | -23.71% | -17.58% |
| All-Time High | ₹348.45 (Dec 02, 2024) | ₹167.90 (Jan 11, 2016) |
| % from All-Time High | -73.20% | -47.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.20% |
| Quarterly Earnings Growth | -0.56% | 2.70% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.03% |
| Operating Margin (TTM) | 0.07% | 0.07% |
| Return on Equity (TTM) | 0.14% | 0.09% |
| Debt to Equity (MRQ) | 0.00 | 197.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹80.33 | ₹49.68 |
| Cash per Share (MRQ) | ₹22.38 | ₹5.74 |
| Operating Cash Flow (TTM) | ₹161.60M | ₹74.55M |
| Levered Free Cash Flow (TTM) | ₹120.93M | ₹72.15M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.63% |
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
Valuation & Enterprise Metrics Analysis: Par Drugs and Chemicals Ltd. vs Bal Pharma Ltd.
| Metric | PAR (Jul 27, 2025) | BALPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.15 | 15.34 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | 0.06 |
| Price to Sales (TTM) | 1.34 | 0.40 |
| Price to Book (MRQ) | 1.37 | 1.57 |
| Market Capitalization | ||
| Market Capitalization | ₹1.36B | ₹1.24B |
| Enterprise Value | ₹1.08B | ₹2.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.07 | 0.87 |
| Enterprise to EBITDA | 5.55 | 11.21 |
| Risk & Other Metrics | ||
| Beta | -0.39 | 0.35 |
| Book Value per Share (MRQ) | ₹80.33 | ₹49.68 |
Financial Statements Comparison: Par Drugs and Chemicals Ltd. vs Bal Pharma Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | PAR (2025) | BALPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 1.01B | 2.94B |
| Cost of Goods Sold | 381.30M | 1.61B |
| COGS % of Revenue | 37.8% | 54.8% |
| Gross Profit | 628.43M | 1.33B |
| Gross Margin | 62.2% | 45.2% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 158.55M | 201.02M |
| Operating Margin | 15.7% | 6.8% |
| EBITDA | 216.52M | 294.33M |
| EBITDA Margin | 21.4% | 10.0% |
| Pre-Tax Income | 179.23M | 51.37M |
| Pre-Tax Income % of Revenue | 17.8% | 1.7% |
| Income Tax | 45.65M | -20.99M |
| Income Tax % of Revenue | 4.5% | -0.7% |
| Net Income (Profit) | 133.58M | 72.37M |
| Profit Margin | 13.2% | 2.5% |
Balance Sheet & Liquidity Metrics
| Metric | PAR (2025) | BALPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 275.77M | 17.52M |
| Total Current Assets | 548.61M | 2.35B |
| Total Current Assets % of Revenue | 54.3% | 79.8% |
| Total Current Liabilities | 165.69M | 2.20B |
| Total Current Liabilities % of Revenue | 16.4% | 74.6% |
| Long-Term Debt | 0 | 326.90M |
| Long-Term Debt % of Revenue | 0.0% | 11.1% |
| Total Shareholders Equity | 989.75M | 774.04M |
| Retained Earnings | N/A | 273.10M |
| Retained Earnings % of Revenue | 0.0% | 9.3% |
| Property, Plant & Equipment | 389.15M | 709.91M |
Cash Flow Statement Comparison
| Metric | PAR (2025) | BALPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 113.58M | 74.55M |
| Operating Cash Flow % of Revenue | 11.2% | 2.5% |
| Capital Expenditures | -12.27M | -187.87M |
| Free Cash Flow | 149.34M | 15.28M |
| FCF Margin | 14.8% | 0.5% |
| Debt Repayment | 0 | -49.49M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PAR | BALPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 12.30M | 15.92M |
| Float Shares | 2.67M | 5.45M |
| % Held by Insiders | N/A | 65.53% |
| % Held by Institutions | N/A | 0.00% |
| % Held by Public | N/A | 34.47% |
Dividend Analysis & Yield Comparison: Par Drugs and Chemicals Ltd. vs Bal Pharma Ltd.
| Metric | PAR | BALPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.20 |
| Last 12-Month Dividend Yield | N/A | 1.63% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹1.13 |
| 3-Year Avg Dividend Yield | N/A | 1.14% |
| 3-Year Total Dividends | ₹0.00 | ₹3.40 |
| Ex-Dividend Date | N/A | Sep 18, 2025 |